Toggle Nav
Close
  • Menu
  • Setting

ML-7 hydrochloride

Catalog No.
A3626
Myosin light chain kinase inhibitor
Grouped product items
SizePriceStock Qty
10mM (in 1mL DMSO)
$50.00
Please inquiry
10mg
$61.00
Please inquiry
50mg
$287.00
Please inquiry

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

Ki = 300 nM

ML-7 is a myosin light chain kinase inhibitor.

Great attention has been gained to the role of myosin light chain kinase (MLCK) pathway in the development of cardiovascular disease and I/R injury. MLCK pathway has been reported to be involved in the pathology of cardiovascular disorders, and the MLCK inhibition could protect heart from I/R injury by regulation of phosphorylation of MLC.

In vitro: Rats with myocardial infarction were intravenously infused with rhNRG-1. The cMLCK expression and phosphorylated MLC-2v were up-regulated in rat treated with rhNRG-1 significantly. Moreover, the restoration of rhNRG-1-induced sarcomeric organization in serum-free cultured neonatal rat cardiomyocytes with rhNRG-1 was inhibited by ML-7 [1].

In vivo: Administration of ML-7 from 10 min before ischemia to the first 10 min of reperfusion led to a significant recovery of heart contractility. Gel analyses of two-dimensional electrophoresis revealed eight proteins with decreased levels in I/R hearts. Six proteins involved in energy metabolism, which were cytochrome b-c1 complex subunit 1, ATP synthase beta subunit, cytochrome c oxidase subunit, mitochondrial NADHdehydrogenase, NADHdehydrogenase iron-sulfur protein 8, and succinyl-CoA ligase subunit. The other two protein levels decreased in I/R hearts, which were peroxiredoxin-2 and tubulin. In addition, ML-7 treatment increased the level of succinyl-CoA ligase, which was a key enzyme involved in the citric acid cycle [2].

Clinical trial: N/A

References:
[1] Gu X,Liu X,Xu D,Li X,Yan M,Qi Y,Yan W,Wang W,Pan J,Xu Y,Xi B,Cheng L,Jia J,Wang K,Ge J,Zhou M.  Cardiac functional improvement in rats with myocardial infarction by up-regulating cardiac myosin light chain kinase with neuregulin. Cardiovasc Res.2010 Nov 1;88(2):334-43.
[2] Lin HB,Cadete VJ,Sawicka J,Wozniak M,Sawicki G.  Effect of the myosin light chain kinase inhibitor ML-7 on the proteome of hearts subjected to ischemia-reperfusion injury. J Proteomics.2012 Sep 18;75(17):5386-95.

Product Citation

Chemical Properties

StorageStore at -20°C
M.Wt452.74
Cas No.110448-33-4
FormulaC15H18ClIN2O2S
SynonymsML 7 hydrochloride
Solubilityinsoluble in EtOH; ≥15.95 mg/mL in DMSO; ≥8.82 mg/mL in H2O with gentle warming and ultrasonic
Chemical Name1-((5-iodonaphthalen-1-yl)sulfonyl)-1,4-diazepane hydrochloride
SDFDownload SDF
Canonical SMILESIC1=CC=CC2=C1C=CC=C2S(N3CCCNCC3)(=O)=O.Cl
Shipping ConditionEvaluation sample solution: ship with blue ice. All other available sizes: ship with RT, or blue ice upon request.
General tipsFor obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Protocol

Cell experiment [1]:

Cell lines

Primary neonatal cardiomyocytes

Preparation method

Soluble in DMSO >15.95mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

10 μM, 24h

Applications

The restoration of rhNRG-1(Recombinant human neuregulin-1)-induced sarcomeric organization in serum-free cultured neonatal rat cardiomyocytes with rhNRG-1 was inhibited by ML-7. RhNRG-1 could improve cardiac function in experimental heart failure models.

Animal experiment [2]:

Animal models

two-month-old male New Zealand white rabbits

Dosage form

1 mg/kg/day, 12 weeks, oral administration

Application

ML7 might ameliorate VED(Vascular endothelial dysfunction) and AS(atherosclerosis) by regulating the TJ(tight junction) proteins ZO1(zona occludens) and occludin in a rabbit model of atherosclerosis via mechanisms involving MLCK(myosin light chain kinase) and MLC phosphorylation.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Gu X1, Liu X, et al, Cardiac functional improvement in rats with myocardial infarction by up-regulating cardiac myosin light chain kinase with neuregulin. Cardiovasc Res. 2010 Nov 1;88(2):334-43. doi: 10.1093/cvr/cvq223. Epub 2010 Jul 8.

[2]. Cheng X1, Wang X2, et al, Myosin light chain kinase inhibitor ML7 improves vascular endothelial dysfunction via tight junction regulation in a rabbit model of atherosclerosis. Mol Med Rep. 2015 Sep;12(3):4109-16. doi: 10.3892/mmr.2015.3973. Epub 2015 Jun 22.

Quality Control